Pfizer, Regeneron, Roche/Genentech, Sanofi, Selecta, Takeda, UCB, and Viela Bio, Grant/research support from: AbbVie, Aclaris, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Gilead, Idorsia, Novartis, Oscotec, Pfizer, Regeneron, Roche/Genentech, Sanofi, Selecta, Takeda, UCB, and Viela Bio, Jerzy Swierkot Speakers bureau: AbbVie, Accord, BMS, Janssen, MSD, Pfizer, Roche, Sandoz, and UCB, Consultant of: AbbVie, Accord, BMS, Janssen, MSD, Pfizer, Roche, Sandoz, and UCB, Grant/research support from: AbbVie, Accord, BMS, Janssen, MSD, Pfizer, Roche, Sandoz, and UCB, Alan Friedman Shareholder of: May own stock or options in AbbVie, Employee of: AbbVie, Nasser Khan Shareholder of: May own stocks or options in AbbVie, Employee of: AbbVie, Yihan Li Shareholder of: May own stocks or options in AbbVie, Employee of: AbbVie, Xianwei Bu Shareholder of: May own stocks or options in AbbVie, Employee of: AbbVie, Justin Klaff Shareholder of: May own stock or options in AbbVie, Employee of: AbbVie, Vibeke Strand Consultant of: AbbVie, Amgen, Arena, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Genentech/Roche, Gilead, GSK, Ichnos, Inmedix, Janssen, Kiniksa, MSD, Myriad Genetics, Novartis, Pfizer, Regeneron, Sandoz, Sanofi, Setpoint, and UCB

DOI: 10.1136/annrheumdis-2021-eular.530

POS0656

RELATIONSHIP BETWEEN CHANGES IN LIPID LEVELS AND IMPROVEMENT IN DISEASE ACTIVITY OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB TREATMENT: POOLED ANALYSIS OF DATA FROM TWO PHASE 3 STUDIES

C. Charles-Schoeman¹, J. T. Giles², N. Lane³, E. Choy⁴, H. Camp⁵, Y. Song⁵, S. Anyanwu⁶, I. McInnes⁶. ¹University of California, Rheumatology, Los Angeles, United States of America; ²Columbia University, Rheumatology, New York, United States of America; ³University of California, Davis, Sacramento, United States of America; ⁴Cardiff University, School of Medicine, Cardiff, United Kingdom; ⁵AbbVie Inc., Rheumatology, North Chicago, United States of America; ⁶University of Glasgow, Rheumatology, Glasgow, United Kingdom

Background: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor engineered to have greater selectivity for JAK1 vs JAK2, JAK3, and tyrosine kinase 2, and is approved for the treatment of RA. Across 2 double-blind, placebo (PBO)-controlled Phase 3 studies of UPA in patients with RA, after an initial increase through Week 8, lipid levels remained stable up to Week 24.^{1,2} Previous studies of JAK or IL-6 receptor inhibitors have reported a negative correlation between changes in lipid levels and RA disease activity.^{3,4}

Objectives: To determine the relationship between changes in lipid levels and disease activity outcomes in patients with RA treated with UPA.

Methods: Patients with RA and an inadequate response to conventional synthetic/biologic DMARDs (cs/bDMARD-IR) from SELECT-NEXT/SELECT-BEYOND, respectively, were randomized to receive UPA 15 mg once daily (QD), UPA 30 mg QD, or PBO for 12 weeks followed by an extension of up to 5 years; patients randomized to PBO switched to UPA 15 or 30 mg after 12 weeks. Spearman correlations of maximum changes from baseline (BL) through Week 12 in fasting-state lipid levels (low- and high-density lipoprotein cholesterol [LDL-C; HDL-C], and total cholesterol [TC]) with clinical disease activity outcomes measured by change from BL in Clinical Disease Activity Index (CDAI), DAS of 28 joints using CRP (DAS28[CRP]), tender/swollen joint count in 28 joints (TJC28/SJC28), and pain by visual analog scale (VAS) at Weeks 12 and 24, were determined. Spearman correlations of maximum changes from BL in lipid levels and CRP through Week 12 were also determined.

Results: Available fasting samples from 1,160 pooled patients (UPA 15 mg, n=386; UPA 30 mg, n=384; PBO, n=390) were included. Modest, but statistically significant, negative correlations were observed between maximum changes from BL in TC through Week 12 and change from BL in CDAI, DAS28[CRP], SJC28, and pain (VAS) at Week 12 with UPA 15 or 30 mg (Figure 1); similar trends were observed at Week 24. Significant correlations between changes in LDL-C and HDL-C and disease activity outcomes were also observed, but were not consistent across UPA doses and time points. No significant correlations were noted between changes in lipid levels and disease activity outcomes in the PBO group. Statistically significant weak negative relationships were observed between maximum changes from BL in lipid levels and CRP levels through Week 12 with UPA 15 mg (HDL-C and TC) or UPA 30 mg (LDL-C and TC) (Table 1).

Conclusion: In this large pooled data set of patients receiving UPA, increases in lipid levels showed modest, but statistically significant, correlations with improvement in clinical disease activity outcomes in patients with cs/bDMARD-IR RA. These results add to evidence suggesting a relationship between systemic inflammation and lipid metabolism in patients with RA, which is modifiable with effective interventions, and reinforce the importance of monitoring for hyperlipidemia in these patients.

REFERENCES:

- [1] Burmester GR, et al. *Lancet* 2018;391:2503–12.
- [2] Genovese MC, et al. *Lancet* 2018;391:2513–24.

- [3] Kremer JM, et al. *Arthritis Rheumatol* 2017;69:943–52.
- [4] Cacciapaglia F, et al. *Mediators Inflamm* 2018;2018:2453265.

Figure. Spearman correlations of maximum changes from BL in lipid levels through Week 12 with disease activity outcomes at Weeks 12 and 24

	Week 12			Week 24			Key*
	LDL-C	HDL-C	TC	LDL-C	HDL-C	TC	
CDAI	-0.117* (n=286)	-0.136* (n=288)	-0.160** (n=284)	-0.124* (n=278)	-0.147* (n=280)	-0.179** (n=280)	0 to -0.1 No or very weak correlation
DAS28[CRP]	-0.116 (n=282)	-0.022 (n=285)	-0.158** (n=285)	-0.147* (n=284)	-0.054 (n=287)	-0.157** (n=287)	-0.1 to -0.2 Very weak correlation
TJC28	-0.075 (n=281)	-0.071 (n=281)	-0.076 (n=281)				-0.2 to -0.3 Weak correlation
SJC28	-0.125* (n=299)	-0.189** (n=301)	-0.195** (n=301)	-0.151** (n=302)	-0.143* (n=292)	-0.185** (n=294)	
Pain (VAS)	-0.191** (n=296)	-0.086 (n=301)	-0.240*** (n=301)	-0.224*** (n=302)	-0.117 (n=276)	-0.264*** (n=276)	
LDL-C	-0.068 (n=301)	-0.074 (n=301)	-0.11 (n=301)				
HDL-C	-0.093 (n=305)	-0.066 (n=307)	-0.098 (n=307)	-0.084 (n=295)	-0.062 (n=297)	-0.097 (n=297)	
TC	-0.106 (n=305)	-0.01 (n=305)	-0.128* (n=305)	-0.112 (n=277)	-0.009 (n=279)	-0.098 (n=279)	
LDL-C	-0.116* (n=302)	-0.067 (n=307)	-0.140* (n=307)	-0.166** (n=307)	-0.069 (n=297)	-0.195** (n=294)	
HDL-C	-0.118* (n=305)	-0.023 (n=305)	-0.161** (n=305)	-0.126* (n=277)	-0.043 (n=279)	-0.132* (n=279)	
TC	-0.046 (n=303)	-0.069 (n=303)	-0.067 (n=303)				
LDL-C	-0.046 (n=302)	-0.184** (n=304)	-0.132* (n=304)	-0.047 (n=273)	-0.192*** (n=273)	-0.095 (n=273)	
HDL-C	-0.118* (n=299)	-0.044 (n=301)	-0.169** (n=301)	-0.184** (n=273)	-0.037 (n=275)	-0.208*** (n=275)	
TC	-0.046 (n=301)	-0.093 (n=301)	-0.043 (n=301)				

*p<0.05, **p<0.01, ***p<0.001.

BL, baseline; CDAI, Clinical Disease Activity Index; DAS28[CRP], DAS of 28 joints using CRP; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PBO, placebo; QD, once daily; SJC28, swollen joint count in 28 joints; TC, total cholesterol; TJC28, total joint count in 28 joints; UPA, upadacitinib; VAS, visual analog scale.

Table 1. Spearman correlation of maximum changes from BL in lipid levels through Week 12 with maximum change from BL in CRP through Week 12

	UPA 15 mg QD	UPA 30 mg QD	PBO
LDL-C	-0.099 (n=303)	-0.174** (n=302)	-0.053 (n=303)
HDL-C	-0.184** (n=305)	-0.087 (n=304)	-0.024 (n=303)
TC	-0.189*** (n=305)	-0.236*** (n=304)	-0.056 (n=303)

p<0.01, *p<0.001.

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PBO, placebo; QD, once daily; TC, total cholesterol; UPA, upadacitinib

Acknowledgements: AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing assistance was provided by Frances Smith, PhD, of 2 the Nth, which was funded by AbbVie.

Disclosure of Interests: Christina Charles-Schoeman Consultant of: AbbVie, Gilead, Pfizer, and Regeneron-Sanofi., Grant/research support from: AbbVie, Bristol-Myers Squibb, and Pfizer, Jon T. Giles Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, and Gilead, Grant/research support from: Pfizer, Nancy Lane Speakers bureau: Amgen and Mallinckrodt, Consultant of: Amgen, Mallinckrodt, Pfizer, and Roche, Ernest Choy Speakers bureau: AbbVie, Amgen, AstraZeneca, Bio-Cancer, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Chugai Pharma, Eli Lilly, Ferring Pharmaceuticals, GlaxoSmithKline, Hospira, Janssen, Merck Sharp & Dohme, Napp, Novimmune, Novartis, ObsEva, Pfizer, Regeneron, Roche, R-Pharm, Sanofi, SynAct Pharma, Synovate, Tonix, and UCB, Grant/research support from: AbbVie, Amgen, AstraZeneca, Bio-Cancer, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Chugai Pharma, Eli Lilly, Ferring Pharmaceuticals, GlaxoSmithKline, Hospira, Janssen, Merck Sharp & Dohme, Napp, Novimmune, Novartis, ObsEva, Pfizer, Regeneron, Roche, R-Pharm, Sanofi, SynAct Pharma, Synovate, Tonix, and UCB, Heidi Camp Shareholder of: AbbVie, Employee of: AbbVie, Yanna Song Shareholder of: AbbVie, Employee of: AbbVie, Samuel Anyanwu Shareholder of: AbbVie, Employee of: AbbVie, Iain McInnes Consultant of: AbbVie, Celgene, Janssen, Novartis, and UCB, Grant/research support from: Celgene, Janssen, Novartis, Pfizer Inc., Roche, and UCB

DOI: 10.1136/annrheumdis-2021-eular.606

POS0657

GEOGRAPHIC VARIATION OF SAFETY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM

B. Combe¹, T. Matsubara², A. Pechonkina³, Y. Tan⁴, Z. Yin⁵, J. Hong⁵, R. Besuyen⁶, A. Gomez-Centeno⁷, M. H. Buch⁸. ¹University of Montpellier, Department of Rheumatology, Montpellier, France; ²Matsubara Mayflower Hospital, Department of Orthopaedic Surgery, Kato, Japan; ³Gilead